LJPC 401

Drug Profile

LJPC 401

Alternative Names: LJPC-401; Synthetic human hepcidin - La Jolla Pharmaceutical

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM
  • Developer INSERM; La Jolla Pharmaceutical Company
  • Class Anti-infectives; Antimicrobial cationic peptides; Peptide hormones; Peptides; Proteins
  • Mechanism of Action Hepcidin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Beta-thalassaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemochromatosis
  • Phase I Iron overload

Most Recent Events

  • 18 Dec 2017 Phase-II clinical trials in Haemochromatosis in USA (SC)
  • 04 Dec 2017 Clinical trials in Iron overload in World, including USA (SC)
  • 17 May 2017 La Jolla Pharmaceutical plans a phase I trial in Healthy volunteers in Australia (ACTRN12617000689370)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top